Updated 2026-09 · 5 min read
Burn-T is a dual-agonist metabolic peptide engaging the GIP and GLP-1 receptors. This guide reviews the mechanism of dual-receptor agonism as reported in preclinical work and the SURPASS and SURMOUNT trial literature. It is a research-use compound and is not for use in humans or animals.
Dual incretin agonism
Combining GIP and GLP-1 receptor agonism in one molecule engages two incretin pathways central to insulin secretion and energy balance in research models. The dual mechanism is the basis of the metabolic and body-composition endpoints studied for the compound, and distinguishes it from single GLP-1 agonism.
Literature context
The dual agonist has been characterized in the SURPASS and SURMOUNT trial programs and in preclinical work. That literature is summarized here as mechanism context only, with no claim of safety, efficacy, or suitability for any use.
In the catalog
This material is synthesized from publicly available preclinical literature and industry documentation for qualified laboratory researchers. It is not medical, veterinary, therapeutic, or diagnostic advice. All compounds are supplied and discussed solely for in-vitro laboratory research and are not for human or animal use.